readthroughSign in
Nov 12, 2026Quarterly update

Altimmune reports Q3 2026 results as pemvidutide programs advance in MASH and AUD

The company said its PERFORMA Phase 3 MASH trial is progressing as planned and an FDA End-of-Phase 2 meeting for alcohol use disorder is set for December 2026.

Altimmune reported third quarter 2026 financial results and a business update on November 12, 2026. CEO and Chairman Jerry Durso said the company is executing a strategy of building a liver franchise around pemvidutide, with its global PERFORMA Phase 3 trial in MASH ramping up.1

In the MASH program, the global PERFORMA Phase 3 trial is progressing as planned, with 52-week topline data expected in 2029.1 The drug previously received Breakthrough Therapy Designation from the FDA based on 24-week data from the IMPACT Phase 2b trial.1

For alcohol use disorder, positive RECLAIM Phase 2 data were highlighted in a late-breaking oral presentation at AASLD The Liver Meeting 2026, and an End-of-Phase 2 meeting with the FDA for the AUD program is scheduled for December 2026.1 Durso said the company will leverage its RECLAIM data in that meeting to discuss a Phase 3 registrational program.1

In alcohol-associated liver disease, enrollment is complete in the RESTORE Phase 2 trial, with topline data expected in the second half of 2027.1

The company also disclosed corporate changes: in October 2026 it appointed Peter Greenleaf and Alex Howarth to its Board of Directors, and in November 2026 it relocated its headquarters to Morristown, New Jersey.1

On finances, Altimmune reported $480 million in cash, cash equivalents and investments as of September 30, 2026.1 R&D expenses were $27.0 million for the quarter, up from $15.0 million a year earlier, driven primarily by the ongoing PERFORMA and RESTORE trials.1 Net loss for the quarter was $31.6 million, or $0.15 per share, compared with a net loss of $19.0 million, or $0.21 per share, in the same period of 2025.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.